Last reviewed · How we verify

IMOVAX POLIO®: Inactive Poliovirus Vaccine — Competitive Intelligence Brief

IMOVAX POLIO®: Inactive Poliovirus Vaccine (IMOVAX POLIO®: Inactive Poliovirus Vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inactivated viral vaccine. Area: Immunology / Infectious Disease.

marketed Inactivated viral vaccine Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

IMOVAX POLIO®: Inactive Poliovirus Vaccine (IMOVAX POLIO®: Inactive Poliovirus Vaccine) — Sanofi Pasteur, a Sanofi Company. IMOVAX POLIO stimulates the immune system to produce antibodies against all three types of poliovirus by introducing inactivated (killed) virus particles.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
IMOVAX POLIO®: Inactive Poliovirus Vaccine TARGET IMOVAX POLIO®: Inactive Poliovirus Vaccine Sanofi Pasteur, a Sanofi Company marketed Inactivated viral vaccine
IPV-Al IPV-Al AJ Vaccines A/S marketed Inactivated viral vaccine Poliovirus serotypes 1, 2, and 3
EV71 inactived vaccine(Vero cells) EV71 inactived vaccine(Vero cells) Sinovac Biotech Co., Ltd marketed inactivated viral vaccine Enterovirus 71 (EV71) viral antigens
Sabin IPV Sabin IPV Centers for Disease Control and Prevention, China marketed inactivated viral vaccine poliovirus serotypes 1, 2, and 3
SARS-CoV-2 Inactivated Vaccine SARS-CoV-2 Inactivated Vaccine PT Bio Farma marketed Inactivated viral vaccine
HepA-I HepA-I Sinovac Biotech Co., Ltd marketed Inactivated viral vaccine Hepatitis A virus (HAV)
fIPV (0.1mL) IM fIPV (0.1mL) IM Centers for Disease Control and Prevention marketed inactivated viral vaccine poliovirus serotypes 1, 2, and 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inactivated viral vaccine class)

  1. Sinovac Biotech Co., Ltd · 9 drugs in this class
  2. Sanofi Pasteur, a Sanofi Company · 9 drugs in this class
  3. GlaxoSmithKline · 5 drugs in this class
  4. Valneva Austria GmbH · 4 drugs in this class
  5. Medical University of Vienna · 3 drugs in this class
  6. Centers for Disease Control and Prevention · 3 drugs in this class
  7. China National Biotec Group Company Limited · 2 drugs in this class
  8. Statens Serum Institut · 2 drugs in this class
  9. Institute of Medical Biology, Chinese Academy of Medical Sciences · 2 drugs in this class
  10. Crucell Holland BV · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IMOVAX POLIO®: Inactive Poliovirus Vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/imovax-polio-inactive-poliovirus-vaccine. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: